Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$19.79M$19.79M+130.8% vs Q3 2017 Net Income-$38.35M-$38.35MN/M vs Q3 2017 EPS Diluted-$0.49-$0.49N/M vs Q3 2017 Gross Profit$12,210,000+62.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$35,876,000N/M Free Cash Flowderived-$39,334,000N/M Margins · derivedGross margin61.7%−26.0 pt vs Q3 2017
Operating margin-211.2%+270.8 pt vs Q3 2017
Net margin-193.8%+294.6 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end